Public trust and the COVID-19 vaccination campaign: lessons from the Philippines as it emerges from the Dengvaxia controversy.

Published on Aug 19, 2021in International Journal of Health Planning and Management
· DOI :10.1002/HPM.3297
Ronald U Mendoza17
Estimated H-index: 17
(Ateneo de Manila University),
Manuel M Dayrit2
Estimated H-index: 2
(Ateneo de Manila University)
+ 1 AuthorsMadeline Mae A Ong (Ateneo de Manila University)
While the entire world prepares and begins to roll out COVID-19 vaccines, the Philippines is still reeling from the consequences of the Dengvaxia controversy in 2016. Those highly political events led to the erosion of public trust in leaders and a significant damage to vaccine confidence in the country, now potentially impacting the uptake of COVID-19 vaccines. We discuss how public trust and confidence can be rehabilitated through accountability, transparency, and proper communication from the most trusted sources of the population. We also highlight key lessons for policymakers and leaders on allowing science to take the front seat, and politics behind, for the safety and well-being of the people during this public health crisis.
📖 Papers frequently viewed together
20212.50BMJ Open
3 Authors (J. Vikse, ..., K. O’Doherty)
1 Citations
1 Citations
#1Gideon Lasco (Ateneo de Manila University)H-Index: 7
#2Vincen Gregory Yu (Ateneo de Manila University)H-Index: 1
### Summary box In 2016, the Philippines embarked on an unprecedented mass immunisation campaign against dengue fever, becoming the first Asian nation to authorise the commercial use of Dengvaxia, the dengue vaccine manufactured by the French pharmaceutical Sanofi Pasteur.1 In December 2017, nearly 2 years since the campaign started, Sanofi announced that Dengvaxia may actually cause ‘more severe disease’ in those who have not had previous dengue infection.2 By then, over 800,000 Filipino school...
3 CitationsSource
#1Alexandre de Figueiredo (Imperial College London)H-Index: 6
#2Clarissa Simas (Lond: University of London)H-Index: 4
Last. Heidi J. Larson (Lond: University of London)H-Index: 58
view all 5 authors...
Summary Background There is growing evidence of vaccine delays or refusals due to a lack of trust in the importance, safety, or effectiveness of vaccines, alongside persisting access issues. Although immunisation coverage is reported administratively across the world, no similarly robust monitoring system exists for vaccine confidence. In this study, vaccine confidence was mapped across 149 countries between 2015 and 2019. Methods In this large-scale retrospective data-driven analysis, we examin...
185 CitationsSource
#1Manuel M Dayrit (Ateneo de Manila University)H-Index: 2
#2Ronald U Mendoza (Ateneo de Manila University)H-Index: 17
Last. Sheena Valenzuela (Ateneo de Manila University)H-Index: 1
view all 3 authors...
In 2016 the Philippine Department of Health (DOH) introduced a novel dengue vaccine in a mass immunization program to reduce the substantial economic and social burden of the disease on households and the government. The vaccine manufacturer's announcement regarding new findings on the small but increased risk of severe dengue for vaccinated seronegative patients caused turmoil as various people claimed that the vaccine caused deaths and that health authorities are corrupt. While health departme...
10 CitationsSource
#1Gideon Lasco (UP: University of the Philippines Diliman)H-Index: 7
#2Heidi J. Larson (Lond: University of London)H-Index: 58
ABSTRACTVarious factors have been implicated in vaccine hesitancy and loss of vaccine confidence, but the specific ways and particular moments in which immunisation programmes and vaccine scares ar...
12 CitationsSource
#1Stefan Flasche (Lond: University of London)H-Index: 35
#2Annelies Wilder-Smith (Lond: University of London)H-Index: 65
Last. Pete Smith (Lond: University of London)H-Index: 211
view all 4 authors...
Background: Dengvaxia was used in the Philippines to vaccinate 9-10-year-old school children, living in areas highly endemic for dengue. After about 830,000 had received at least 1 of 3 recommended doses, risks of enhanced disease in dengue-naive vaccinees were reported. Methods: We used Phase 3 trial data to derive the proportions of cases of hospitalised and severe dengue that might have been prevented by the Philippines vaccination programme and, among those cases that may occur in vaccinees,...
10 CitationsSource
Seventy people, most of them children, have died of measles in the Philippines since the start of 2019,1 the country’s health ministry has said, as many as were killed by the virus in the entire World Health Organization European region in all of 2018.2 There were over 18 000 cases of measles in the Philippines in 2018, compared with about 2400 in 2017. Measles vaccination rates fell from a 2014 high of 88% to 73% in 2017, then plummeted to about 55% last year. The sharp drop came in the wake of...
15 CitationsSource
#2Joachim HombachH-Index: 31
Last. Terry Nolan (University of Melbourne)H-Index: 51
view all 18 authors...
Summary The Strategic Advisory Group of Experts (SAGE) on Immunization advises WHO on global policies for vaccines. In April, 2016, SAGE issued recommendations on the use of the first licenced dengue vaccine, CYD-TDV. In November, 2017, a retrospective analysis of clinical trial data, stratifying participants according to their dengue serostatus before the first vaccine dose, showed that although in high seroprevalence settings the vaccine provides overall population benefit, there was an excess...
77 CitationsSource
#1Heidi J. Larson (Lond: University of London)H-Index: 58
#2Kenneth Hartigan-Go (Asian Institute of Management)H-Index: 5
Last. Alexandre de Figueiredo (Lond: University of London)H-Index: 6
view all 3 authors...
ABSTRACTIn November 2017, it was announced that the new dengue vaccine (“Dengvaxia”) had risks for those not previously exposed to dengue. While some countries proceeded with adjusting guidance acc...
53 CitationsSource
#1Khunsha Fatima (DUHS: Dow University of Health Sciences)H-Index: 1
#2Najah Irfan Syed (BU: Bahria University)H-Index: 1
41 CitationsSource
Background In light of the increasing rate of dengue infections throughout the world despite vector-control measures, several dengue vaccine candidates are in development. Methods In a phase 3 efficacy trial of a tetravalent dengue vaccine in five Latin American countries where dengue is endemic, we randomly assigned healthy children between the ages of 9 and 16 years in a 2:1 ratio to receive three injections of recombinant, live, attenuated, tetravalent dengue vaccine (CYD-TDV) or placebo at m...
653 CitationsSource
Cited By0